Follow-up survey of nivolumab, pembrolizumab and ipilimumab in Sapporo City General Hospital

Follow-up survey of nivolumab, pembrolizumab and ipilimumab in Sapporo City General Hospital - Follow-up survey of nivolumab, pembrolizumab and ipilimumab in our institute

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034302

Enrollment

Registered

2018-10-01

Start date

2018-07-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer, malignant melanoma, head and neck cancer, gastric cancer, renal cell cancer, urothelial carcinoma, Hodgkin lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient administered nivolumab, pembrolizumab or ipilimumab

Exclusion criteria

Exclusion criteria: The case that the dosage situation and side effect information of nivolumab, pembrolizumab or ipilimumab cannot confirm from a medical record enough

Design outcomes

Primary

Measure	Time frame
Immune-related adverse events	—

Secondary

Measure	Time frame
Response rate, Overall survival	—

Countries

Japan

Contacts

Public ContactSone Takayuki

Sapporo City General Hospital Department of Gastroenterology

takakikyou@gmail.com011-726-2211

Outcome results